According to the Zhitong Finance App, Ciyao Group (01093) announced its 2017 results, achieving total revenue of about HK$15.462.5 billion, an increase of 25% over the previous year; gross profit of about HK$9.346 billion, an increase of about 48.1% over the previous year; operating profit of about HK$3.482 billion, an increase of 31.4% over the previous year; profit attributable to shareholders of about HK$2,770.5 million, an increase of 31.9% over the previous year; basic profit per share was 45.48 HK cents, with a proposed final dividend of HK15 cents per share.

According to the announcement, the proprietary drug business remains the group's main growth engine. In 2017, sales revenue increased 26.8% to HK$11.374 billion. Among them, the group's innovative drugs continued to grow strongly, with sales revenue reaching HK$6.582 billion, an increase of 37.9%. Innovative drug revenue also increased further from 38.6% in 2016 to 42.6% of the Group's total revenue this year. In 2017, the price of vitamin C products rebounded sharply, so the profitability of the vitamin C business increased dramatically this year.